Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kissei's MRs Provide Drug Safety Data on the Spot
April 9, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 9, 2007
- St. Gallen Consensus Most Commonly Referred to by Japanese Oncologists in Breast Cancer Treatment: Seminar
April 2, 2007
- Personalized Treatment with Irinotecan Starts
April 2, 2007
- Kissei Aims at 20% Share for Urief in FY2007
April 2, 2007
- Risk of Death Reduced in People Examined for Colorectal Cancer
April 2, 2007
- GSK Enhances Oncology Marketing Forces
April 2, 2007
- Risk of Localized Prostate Cancer Reduced by Soy Products
April 2, 2007
- BUSINESS NEWS IN BRIEF
April 2, 2007
- Entecavir Is 1st-Choice Drug for Chronic Hepatitis B: Dr Kumada
April 2, 2007
- Korosho Orders Chugai to Issue "Dear-Doctor Letter" on Tamiflu
April 2, 2007
- NEW PRODUCTS
April 2, 2007
- Relenza in Short Supply
April 2, 2007
- Eli Lilly to Enhance Presence in GP Market: Mr Crenshaw
April 2, 2007
- Council to Propose Strategies to Enhance Global Competitiveness
April 2, 2007
- Eisai Embarks on Antibody Pharmaceuticals Business by Acquiring Morphotek
April 2, 2007
- REGULATORY NEWS IN BRIEF
April 2, 2007
- Suzuken to Place Top Priority on Customer Satisfaction, Promote M&As: New President Ota
April 2, 2007
- JMA Symposium on Stimulation of Clinical Trials
April 2, 2007
- Market for Ethical Drugs in Japan Fell 0.6% in 2006: IMS
April 2, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…